Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Plus Therapeutics ( (PSTV) ).
Plus Therapeutics has entered into a Purchase Agreement with Lincoln Park, which is an accredited investor, to issue and sell securities under exemptions from the registration requirements of the Securities Act. This strategic move allows Plus Therapeutics to raise capital while leveraging regulatory exemptions, potentially impacting its financial strategy and stakeholder interests.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The stock of Plus Therapeutics is significantly hindered by its poor financial performance and challenging valuation. The technical analysis further supports a bearish outlook. While the earnings call offers some positive clinical and financial developments, these are overshadowed by ongoing financial and regulatory difficulties, including potential Nasdaq delisting.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 7,753,313
Technical Sentiment Signal: Sell
Current Market Cap: $6.63M
See more data about PSTV stock on TipRanks’ Stock Analysis page.